BioTime, Inc. (NYSE Amex:BTIM). BioTime announced today the change of its stock ticker symbol on the NYSE Amex. Additionally, BioTime announced today that it is extending the expiration date of its common share purchase warrants that expire on October 31, 2010. BioTime announced that commencing November 2, 2010, the trading symbol of its common shares on the NYSE Amex will change from BTIM to BTX. Because October 31 is a Sunday, BioTime is extending the warrant expiration date and time until 5:00 p.m. New York time on Monday, November 1, 2010. Trading of the warrants on the NYSE Amex will continue through October 29, 2010. BioTime will permit exercises of the warrants to be accepted by the warrant agent through a notice of guaranteed delivery from a bank, a trust company, or a New York Stock Exchange member guaranteeing delivery of a properly completed and executed warrant certificate. Warrant holders who choose to exercise their warrants through a notice of guaranteed delivery must pay the exercise price of their warrants and must deliver the notice of guaranteed delivery to the warrant agent by facsimile telecopy or otherwise not later than 5:00 p.m. New York time on Monday, November 1, 2010. The warrant agent will not honor a notice of guaranteed delivery unless the warrant agent receives payment of the exercise price of the warrants and the notice of guaranteed delivery by 5:00 p.m. New York time on the warrant expiration date, and the warrant agent receives a properly completed and executed warrant certificate by the close of business (5:00 p.m. New York time) on the third business day after the warrant expiration date. Warrant holders who desire to exercise their warrants should deliver their properly completed warrant certificates and notices of guaranteed delivery to the Warrant Agent, American Stock Transfer & Trust Company, by hand, mail, express mail, or overnight courier at the following address:
|American Stock Transfer & Trust Company|
|Attn: Reorganization Department|
|6201 15th Avenue|
|Brooklyn, New York 11219|
BioTime suggests that you send funds for the payment of the warrant exercise price by wire transfer to American Stock Transfer & Trust Company, Warrant Agent, JP Morgan Chase Bank WIRE CLEARING ACCOUNT ABA #021000021, Account 530354624, Attention: Reorg. Dept.Do not send warrant certificates or notices of guaranteed delivery to BioTime. The securities described in this communication may only be offered by means of a prospectus. This communication shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. About BioTime, Inc. BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is developed through subsidiaries focused on specific fields of applications. BioTime develops and markets research products in the field of stem cells and regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. BioTime’s therapeutic product development strategy is pursued through subsidiaries that focus on specific organ systems and related diseases for which there is a high unmet medical need. BioTime’s majority owned subsidiary Cell Cure Neurosciences, Ltd. is developing therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte Corporation is developing therapeutic applications of stem cells to treat orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation, focuses on the therapeutic applications of stem cell technology in cancer. BioTime’s Singapore subsidiary, ES Cell International Pte Ltd, has been at the forefront of advances in human embryonic stem (“hES”) cell technology, having been one of the earliest distributors of hES cell lines to the research community. ESI has produced clinical-grade human embryonic stem cell lines that were derived following principles of good manufacturing practice and currently offers them for potential use in therapeutic product development. In addition to its stem cell products, BioTime develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, and technology for use in surgery, emergency trauma treatment and other applications. BioTime’s lead product, Hextend®, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements. Additional information about BioTime, Embryome Sciences, Cell Cure, OrthoCyte, OncoCyte, BioTime Asia, and ESI can be found on the web at www.biotimeinc.com. Forward-Looking Statements Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company’s business, particularly those mentioned in the cautionary statements found in the company’s Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0